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HIC1 controls cellular- and HIV-1- 
gene transcription via interactions 
with CTIP2 and HMGA1
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Christian Schwartz1,2,*
Among many cellular transcriptional regulators, Bcl11b/CTIP2 and HGMA1 have been described 
to control the establishment and the persistence of HIV-1 latency in microglial cells, the main viral 
reservoir in the brain. In this present work, we identify and characterize a transcription factor i.e. 
HIC1, which physically interacts with both Bcl11b/CTIP2 and HMGA1 to co-regulate specific subsets of 
cellular genes and the viral HIV-1 gene. Our results suggest that HIC1 represses Tat dependent HIV-1 
transcription. Interestingly, this repression of Tat function is linked to HIC1 K314 acetylation status 
and to SIRT1 deacetylase activity. Finally, we show that HIC1 interacts and cooperates with HGMA1 to 
regulate Tat dependent HIV-1 transcription. Our results also suggest that HIC1 repression of Tat function 
happens in a TAR dependent manner and that this TAR element may serve as HIC1 reservoir at the viral 
promoter to facilitate HIC1/TAT interaction.
Numerous cellular proteins have been described as HIV-1 transcriptional regulators involved in HIV-1 latency1,2. 
Among them proteins belonging to the 7sk non coding RNA (ncRNA) which include Bcl11b/CTIP2 and HMGA1 
appeared to be important in the regulation of early phase, Tat-independent, HIV-1 transcription contributing 
to the establishment and the persistence of HIV-1 latency3. Indeed it was shown that CTIP2 cooperates with 
LSD1 and favors the formation of a compacted inactive-chromatin (heterochromatin) and the establishment of 
HIV-1 latency in microglial cells, the CNS resident macrophages4–7. Associated to the cellular 7SKsnRNA, CTIP2 
represses P-TEFb functions and thus P-TEFb-sensitive gene transcription. The cellular High Mobility Group 
AT-Hook 1 (HMGA1) has been described to act in synergy with CTIP2 by recruiting CTIP2-repressed P-TEFb 
on the HIV-1 promoter and thus preventing HIV-1 reactivation4,5. In addition we showed that these two proteins 
are recruited to cellular target promoters to regulate gene expressions5. Additional roles of HMGA1 and CTIP2 
during HIV-1 transcription and cellular gene expression remain to be deciphered. We have previously shown that 
CTIP2 relocates the essential viral trans activator of HIV gene expression Tat to heterochromatin protein 1 (HP1) 
containing structures to repress Tat-dependent HIV-1 transcription8. However the precise molecular mechanisms 
underlying this effect are not fully understood.
HMGA1 interacts with a large variety of cellular proteins involved in the regulation of HIV-1 gene transcrip-
tion including SP1 and NF-KB. Moreover, HMGA1 associates with several high and low affinity DNA binding 
sites within the HIV-1 promoter and interacts with the TAR region of the initiated HIV-1 RNA to modulate Tat 
functions. These findings also point out to additional roles of HMGA1 during HIV-1 transcription9,10.
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Identifying cellular factors involved in establishment and maintenance of HIV-1 latency is crucial since it 
helps greatly the development of more rational therapeutically strategies. The two major strategies are
1. Reactivation of virus expression aiming at the reduction of latently infected cellular reservoirs11
2. Reinforcement of HIV-1 repression by targeting transcriptional steps, and thus improving cART12
Therapies that target cellular factors appear even more important from the point of view that some of these 
cellular factors operate in a synergistic manner (e.g. LSD1 and CTIP27 or HMGA1 and CTIP25).
Among new potential HIV-1 transcriptional regulators is the cellular protein Hypermethylated In Cancer 1 
(HIC1). Indeed, it has been shown that CTIP2 and HIC1 share some cellular target genes such as the p21 and the 
p57kip2 genes13–16. Moreover, CTIP2 and HIC1 have been reported to associate with the repressive NurD com-
plex15 suggesting that both factors take part of the same complex repressing common target genes.
HIC1 is a tumor suppressor involved in numerous cellular process including DNA damage response, cell 
survival, and neural development17–19. Loss of heterozygosity (LOH) of Hic1 has been implicated in many can-
cers, such as medulloblastoma or leukemia and has been associated with increased malignancy and poor prog-
nosis20–22. LOH of HIC1 can occur through hypermethylation or deletion of the 17p13.3 region, where the Hic1 
gene is located23. HIC1 is a transcriptional repressor divided into three main regions (Fig. 1). The first domain 
located in the amino-terminal part is an evolutionarily conserved protein-protein interaction motif named BTB/
POZ (Broad complex, Tramtrack and Bric à brac/Pox viruses and Zinc finger)24,25. This region has an auton-
omous transcriptional repressive activity through its interaction with the NAD-dependant class-III histone 
deacetylase SIRT126. The central region contains two phylogenetically conserved sequences. The GLDL225SKK is 
a conserved motif to which binds the C-terminal binding protein (CtBP). Interaction of CtBP with HIC1 confers 
a class-I and –II HDAC-dependant transcriptional repression activity to its later one27. The second motif presents 
a SUMOylation/acetylation switch on MK314HEP. Acetylation of lysine 314 by CBP/P300 has been associated 
to a decrease of HIC1 interaction with its co-repressor. SUMOylation on the other hand has been described to 
activate and potentiate HIC1-mediated transcriptional repression15. Acetylation and SUMOylation compete for 
the same lysine residue28. Finally, the C-terminal part of HIC1 contains five krueppel-like C2H2 zinc fingers. A 
cluster with the last four zinc fingers allows HIC1 to interact with a 5′ C/GNGC/GGGGCAC/ACC-3′ consensus 
sequence in HIC1 target genes, the HIC1 responsive element (HiRe)29. Recently zinc fingers have been described 
to be implicated in the recruitment of SIRT1 promoting HIC1 lysine deacetylation followed by SUMOylation 
favored by HDAC428,30.
Herein we report that HIC1 interacts physically with both CTIP2 and HMGA1 to co-regulate common pan-
els of cellular gene. In addition, we show for the first time that the tumor suppressor HIC1 is able to promote 
Tat-dependent HIV-1 transcriptional silencing in microglial cells. HIC1 induces nicotinamide-sensitive HIV-1 
transcription extinction by cooperating with the deacetylase SIRT1. SIRT1 is known to deacetylate the lysine 
314 in the MKEHP acetylation/SUMOylation switch motif of HIC1. Interestingly a single amino-acid mutation 
in the MKEHP acetylation/SUMOylation switch, which mimics a constitutive acetylation of the lysine 314 is 
sufficient to abrogate HIC1-driven transcriptional repression. Moreover, a mutant mimicking a constitutively 
acetylated HIC1 loses its ability to interact with Tat. We propose that SIRT1-driven HIC1 de-acetylation is a 
critical step which occurs upstream of HIC1/Tat interaction. Finally, we show that HIC1 interacts and cooperates 
with HMGA1 to regulate Tat-dependent transcription of HIV-1 gene.
Results
HIC1 and CTIP2 interact and co-regulate cellular genes expression. We first took advantage of 
global gene expression profiling to identify and compare HIC1 and CTIP2 target genes in microglial cells. For this 
purpose, HIC1 and CTIP2 were either knocked down or overexpressed in microglial cells followed by transcrip-
tome analyses using microarray technology. We defined HIC1 target genes as genes that are concomitantly regu-
lated in statistically significant manner (p < 0.01) upon either knockdown or overexpression of HIC1 (Fig. 2A). 
Among the identified HIC1 targets, 21 (11%) genes were down-regulated and 171 (89%) were up-regulated upon 
Figure 1. Schematic structure of HIC1 and post translational modifications. HIC1 is a transcriptional 
repressor divided in three main regions (A) (1) A BTB/POZ protein-protein interaction domain located in the 
amino-terminal part (2) A HIC1 central domain which contains a MK314HEP conserved sequence, in which 
the lysine 314 (K314) acts as an acetylation/SUMOylation switch (3) A C-terminal part which contains five 
krueppel-like C2H2 zinc fingers. (B) SIRT1 interacts with the HIC1 5 krueppel-like zinc fingers and deacetylates 
K314. SIRT1 recruits also HDAC4 which facilitate SUMOylation of K314.
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HIC1 knockdown. The scatter plot comparing the log2-fold changes in the HIC1 overexpression profile with that 
of the HIC1 knockdown profile reveals a robust negative Pearson correlation (R = − 0.75) indicating that the 
majority of the identified HIC1 target genes are directly regulated (Fig. 2B). As expected, pathway enrichment 
analyses based on these HIC1 target genes show that the ATM DNA damage response pathway as well as the 
apoptosis- and cell cycle control-related pathways are among the most significantly affected pathways (Fig. 2C). 
We have included the gene lists of cellular targets regulated by HIC1 and CTIP2 (supplemental table 1) in order 
to specify their identity.
As in case of HIC1 we defined direct CTIP2 targets as genes that are concomitantly up or down-regulated 
in a statistically significant manner (p < 0.01) in CTIP2 overexpression and knockdown experiments5. Upon 
CTIP2 knock-down, 31 genes (12%) were down-regulated and 227 genes (88%) were up-regulated. The compar-
ison of HIC1 and CTIP2 targets reveals a statistically significant (p < 2.38 × 10−180) common subset of 100 genes 
(Fig. 3A). Scatter plot representations of both gene sets as well as the common subset comparing both HIC1 and 
CTIP2 overexpression (Fig. 3B) and HIC1 and CTIP2 knockdown (Fig. 3C) reveal a strong positive correlation 
between both conditions. Taken together these results suggest that HIC1 and CTIP2 cooperate to regulate cel-
lular genes. To determine if this functional cooperation could result from physical association, we performed 
co-immunoprecipitation experiments. As shown in Fig. 3D, HIC1 associated physically with CTIP2 suggesting 
that the observed functional cooperation may result from physical interactions between the two factors.
HIC1 inhibits HIV-1 gene transcription and the viral expression in microglial cells. We have pre-
viously shown that CTIP2 favors the establishment and the persistence of HIV-1 latency in microglial cells, the 
central nervous system major reservoirs of the virus31. To decipher the role of HIC1 on HIV-1 infection, micro-
glial cells expressing a NL-4.3 provirus were subjected to HIC1 over-expression or HIC1 knock-down (Fig. 4A). 
Since knocking-down HIC1 promoted an increase of the virus expression, over-expressing HIC1 repressed HIV-1 
p24 production. As a control, overexpression and knock-down efficiencies were assessed by RT-qPCR (Fig. 4C). 
Figure 2. Identification of HIC1 target genes. (A) Heatmap of statistically significantly (p < 0.01) 
concordantly regulated genes upon overexpression (HIC1) and knockdown (sh HIC1) of HIC1. The number of 
positively regulated genes (L, red shading) and negatively regulated genes (L, blue shading) is shown together 
with independent biological replicate signals of each condition and control (S). Post-hoc p-values are indicated 
as color code (P). (B) Scatter plot of the genes shown in (A). The log2-fold change upon HIC1 overexpression is 
plotted against the x-axis, the log2-fold change upon HIC1 knockdown is plotted against the y-axis. The Pearson 
correlation coefficient is indicated (R). (C) Gene ontology pathway enrichments based on the genes shown in 
(A). Pathways significantly (p-values as indicated) enriched for HIC1 target genes are listed and the ratio is 
indicated.
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These results argue for a repressive function of HIC1 on HIV-1 expression in microglial cells. Since HIC1 is 
known as a repressor of gene transcription, we next focused on HIC1 functions on HIV-1 gene transcription in 
microglial cells. As shown Fig. 4B, knocking-down HIC1 favored Tat-mediated stimulation of the HIV-1 gene 
promoter. As expected, overexpression of HIC1 in microglial cells repressed Tat activity (Fig. 4B). Of note, the 
knock-down and the overexpression of HIC1 had no significant effect on HIV-1 gene transcription in the absence 
of Tat (data not shown). These results suggest that HIC1 represses HIV-1 expression by counteracting Tat func-
tion at the transcription step of the viral life cycle.
HIC1 colocalizes and interacts with Tat in microglial cells nuclei. Since HIC1 counteracts Tat function, 
we next investigated on the locations and the interactions between the cellular and the viral transcription factors. 
First we looked for the localization of the two proteins by confocal microscopy in microglial cells (Fig. 5A). Both 
proteins displayed a nuclear localization when expressed alone (Fig. 5A lane 1 and 2, column 3). However, Tat was 
expressed in the nucleoplasm and the nucleoli (Fig. 5A lane 1 column 1), while HIC1 was found in the outskirts 
of nuclear ball-like structures (Fig. 5A lane 2 column 2). Interestingly, upon co-expression, Tat relocates and 
co-localizes with HIC1 in the HIC1-induced ball-like structures (Fig. 5A lane 1 vs lane 3 columns 1 and 4). Since 
HIC1 relocates and co-localizes with Tat, we investigated whether both proteins could physically interact. We 
performed immunoprecipitation experiments on nuclear extract from cell expressing Flag-HIC1 and GFP-Tat. As 
shown in Fig. 5B, HIC1 physically associated with Tat suggesting that HIC1-mediated repression of Tat function 
depends on the physical association of the two proteins.
HIC1 functionally interacts with Tat and Sirt1 to control HIV-1 gene transcription. Next we 
hypothesized that SIRT1, the mammalian homolog of Sir2 enzymes, may also be involved in HIC1 mediated 
regulations. Indeed, this class-III NAD+ dependent deacetylase has been described as a co-repressor of HIC1 
and a co-activator of Tat26,32 and Fig. 6 (lane 2). To investigate this point, we evaluated the impact of SIRT1 on 
HIC1-mediated inhibition of Tat function (Fig. 6). Overexpression of WT-SIRT1 did not drastically modify HIC1 
repression of Tat transactivation (Fig. 6: 40% of Tat inhibition lane 1 vs 50% in lane 3). However, overexpression 
Figure 3. HIC1 and CTIP2 cooperate in gene expression regulation. (A) Venn-diagram of HIC1 and 
CTIP2 target genes. HIC1 target genes (red) have been identified as indicated in Fig. 1(A) and CTIP2 target 
genes (blue) have been defined as genes statistically significantly (p < 0.01) concordantly regulated genes upon 
overexpression and knockdown of CTIP2. The common subset is shown in purple. The p-value (hypergeometric 
distribution) for chance occurrence of this overlap is indicated. (B) Scatter plot of the genes shown in (A). The 
log2-fold change upon HIC1 overexpression is plotted against the x-axis, the log2-fold change upon CTIP2 
overexpression is plotted against the y-axis. The Pearson correlation coefficient for each gene set is indicated 
(R). (C) as in (B), but comparing the log2-fold changes in gene expression upon HIC1 knockdown with the 
knockdown of CTIP2. (D) CTIP2 and HIC1 interact physically: HEK293T cells were co-transfected with the 
pNTAP-CTIP2 expression vectors (lane 1 and 2) and the pCDNA3-Flag-HIC1 expression vector (lane 2) or 
the control pCDNA3-Flag vector (lane 1). Complexes immunoprecipitated with the anti-Flag antibodies were 
immunodetected for the presence of tap-CTIP2 and Flag-HIC1 proteins by Western blot as indicated.
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of SIRT1 H363Y mutant completely abrogated HIC1 mediated repression (Fig. 6: lane 5 vs row 1). The single 
amino-acid mutated H363Y SIRT1 variant is catalytically inactive33. These results together suggest that the mutated 
form of SIRT1 competes with the endogenous one to modulate HIC1 function. In addition, our results suggest 
that the deacetylase function of SIRT1 is involved in HIC1-mediated regulation of Tat function. To further vali-
date the role of SIRT1 deacetylase activity on HIC1–mediated repression, we used nicotinamide (NA), the most 
potent inhibitor of SIRT134, and evaluated the impact of its treatment on HIC1 function (Fig. 6). NA treatments 
abolished HIC1-mediated repression of Tat function (Fig. 6 lane 7 vs lane 1), confirming the need of the catalytic 
activity of SIRT1 in the regulation of HIV-1 promoter by HIC1.
HIC1 Lysine 314 is crucial for Tat association and HIC1-mediated repression of the HIV-1 gene 
transcription. The central region of HIC1 contains a MK314HEP conserved sequence, in which the lysine 
314 (K314) acts as an acetylation/SUMOylation switch. Acetylation and deacetylation of HIC1 K314 is respec-
tively under control of the cellular acetyl-transferase CBP/P300 and SIRT128. SIRT1 binds the krueppel-like 
C2H2 zinc fingers in the carboxy-terminal end of HIC1 and promotes deacetylation of K314 by its non-histone 
protein deacetylase activity30. Meanwhile, SIRT1 also recruits HDAC4, known as an E3 ligase of the SUMO 
pathway35, which facilitates the SUMOylation of K314. SUMOylation of HIC1 has previously been associated 
with recruitment of the co-repressor NuRD through the interaction of HIC1 and the subunit MTA1 of NuRD15. 
Single amino-acid modifications in the MK314HE316P sequence modify the post-translational pattern of HIC1. 
Thus mutation of the glutamic acid 316 (E316A) disrupts the SUMOylation ψ KxEx motif and abolishes HIC1 
SUMOylation. The K314 is the target of both SUMOylation and acetylation post-translationnal marks. When K314 
is mutated to an arginine (K314R), HIC1 can neither be acetylated nor SUMOylated28. However mutation of K314 
to glutamine (K314Q) mimics a constitutively acetylated HIC1, probably because the side chain of glutamine is 
similar in charge and structure to an acetylated lysine.
Our results suggest that SIRT1 cooperates with HIC1 to repress HIV-1 transcription. Since SIRT1 deacetylates 
and facilitates SUMOylation of HIC1, we investigated whether these specific post-translational modifications 
could be involved in the repression process. Along with this goal, we investigated the effects of mutated HIC1 
proteins on HIV-1 gene transcription and on the viral expression. As shown in Fig. 7A,B, WT HIC1,effectively 
repressed Tat-mediated transactivation of the HIV-1 promoter (Fig. 7A lane 3 vs lane 2) and p24 production 
(Fig. 7B lane 6 vs lane 5). However, the mutation of the Lysine 314 to a glutamine (K314Q) (Fig. 7A lane 4) but not 
the E316A and K314R mutations (data not shown) abrogated HIC1 repressive function. As attested by expression 
profile, the mutation K314Q did not significantly impact HIC1 expression (Fig. 7C). Hence the impacts of the 
HIC1 mutant K314Q was similar in the context of NL4.3 expressing microglial cells. Indeed, the K314Q mutation 
abrogated HIC1-mediated repression of the HIV-1 expression (Fig. 7B lane 7 versus 6). Since we have reported 
Figure 4. Effect of HIC1 over-expression or knock-down on HIV-1 in microglial cells. Microglial cells were 
transfected either with the pNL-4.3 provirus (A) or the episomal pLTR-luciferase reporter (B) and the indicated 
plasmids. 48-hours later, supernatants were harvested (A) or cells were lysed (B). Viral p24 concentrations were 
titrated in supernatant and normalized relatively to their appropriate empty vector control (A). Cell lysates 
were subjected to luciferase assay, normalized with the renilla luciferase system and expressed as relative Tat 
stimulation with their respective control (B). Nuclear cell extracts were obtained after 48-hours transfection of 
the indicated vectors and subjected to western-blot experiments to detect endogenous knock down and over-
expressed HIC1 (respectively lane 1,2 and 3). As a control we checked the relative HIC1 mRNA following a 
HIC1 knock down (shHIC1) or following overexpression of flag-HIC1 (f-HIC1) (C).
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that HIC1 physically interacts with Tat to repress HIV-1 gene transcription, we further compared the ability of the 
WT and the K314Q mutated HIC1 proteins to interact with Tat. In agreement with the results shown in figure 5, 
WT HIC1 but not the K314Q mutant interacted with Tat (Fig. 7C).
Taken together, our results suggest that mimicry of the acetylation mark on K314 (K314Q) impaired HIC1 
association to Tat, which was correlated with a repressed-transcription and an impaired-expression of the HIV-1.
The TAR region of the HIV-1 gene transcripts is involved in transcriptional repression mediated 
by HIC1. Elongation of HIV-1 gene transcripts is initiated by the binding of the viral Tat protein on the TAR 
region of the initiated transcripts, which in turn recruits P-TEFb and promotes RNApol II processivity. We have 
investigated the impact of the Tat-TAR axis on HIC1 function by evaluating the effects of exogenous TAR RNA 
on the HIV-1 promoter activity. Expression of exogenous TAR RNA in the absence of Tat did not significantly 
affect the basal activity of the HIV-1 promoter (Fig. 8 row 4 vs 1). Moreover, we observed a competition between 
the exogenous TAR RNA and the LTR-TAR region, which, as a consequence, repressed Tat-mediated activation 
(Fig. 8, row 5 vs 2). Surprisingly, exogenous TAR RNA also abrogated HIC1-mediated repression of Tat activity 
(Fig. 8, row 5 vs 6). These results may suggest that HIC1-mediated repression of Tat function occurs in a TAR 
dependent manner.
HIC1 cooperates with HMGA1 to target gene transcriptions. We have previously shown that interaction 
of the cellular transcription factor HMGA1 with TAR modulates Tat-dependent HIV-1 gene transcription36. 
In addition, we have reported that CTIP2-associated P-TEFb complex is recruited by HMGA1 to the HIV-1 pro-
moter and cellular target promoters5. In view of these observations and the above-presented results we examined 
the potential functional and physical interactions of HMGA1with HIC1. First we compared HIC1 and HMGA1 
Figure 5. HIC1 relocates TAT in sub-nuclear ball like structures in which they interact. (A) Microglial cells 
were transfected with pGFP-TAT (row 1), pFlag-HIC1 (row 2) or both (row 3). 48-hours post-transfection cells 
were fixed and stained with TOPRO-3 (column 3) to detect the nucleus. Flag-HIC1 was detected by incubating 
cells with an anti-flag antibody and immunostained with a cyanine 3-labelled secondary antibody (column 2). 
Localization of Flag-HIC1 and GFP-TAT has been acquired by confocal microscopy. (B) HEK293T cells were 
transfected with pGFP-TAT alone or in combination with pFlag-HIC1. 48-hours later cells were lysed and 
nuclear extracts have been subjected to immunoprecipitation with an anti-Flag tag antibody. TAT and HIC1 
were detected by western blot with respectively anti-TAT and anti-Flag antibodies.
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target gene expression profile. HMGA1 target genes have been defined as genes that are concomitantly and sta-
tistically significantly (p < 0.05) regulated upon HMGA1 knockdown and overexpression5. In microglial cells 6 
genes (8%) are down-regulated and 68 genes (92%) are up-regulated upon HMGA1 knockdown. Comparing 
HIC1 targets with HMGA1 targets reveals a statistically significant (p < 2.55 × 10−31) common subset of 20 
genes (Fig. 9A). The HIC1 and HMGA1 target genes show a strong positive correlation when comparing either 
HIC1 overexpression or HMGA1 overexpression (Fig. 9B) and either HIC1 knockdown or HMGA1 knockdown 
(Fig. 9C). Remarkably, this positive correlation is also observed for each target gene set alone, as indicated by 
the Pearson correlation coefficients. We have included the gene lists of cellular targets regulated by HIC1 and 
HMGA1 (supplemental Table 2) in order to specify their identity.
Figure 6. HIC1-mediated TAT-dependent HIV-1 transcription repression process requires SIRT1 
deacetylase activity. Microglial cells were transfected with pLTR-Luc and the indicated expression vector. 
Relative Tat stimulation in the absence (lanes 2, 4 and 6) or in the presence (lanes 1, 3, 5 and 7) of flag_HIC1was 
studied in absence (lanes 1, 4, 5 and 6) or presence of over-expression of either wild-type SIRT1 (lanes 2 and 3)  
or H363Y SIRT1 mutant (lanes 4 and 5). 24-hours after transfection, cells were either untreated (lanes 1,2, 3, 
4 and 5) or incubated with 10 mM nicotinamide (NA) (lanes 6 and 7). 48-hours post-transfection, cells were 
lysed and luciferase activity measured. Values were normalized using renilla luciferase system. Empty vector 
transfection of each condition has been set to one and other transfection points were normalized accordingly.
Figure 7. Acetylation of lysine 314 is detrimental to HIC1 inhibitory activity and disrupts HIC1/TAT 
association. HIC1 central domain contains a MK314HEP conserved sequence, in which the lysine 314 (K314) 
acts as an acetylation/SUMOylation switch (Fig. 1). SIRT1 interacts with the HIC1 5 krueppel-like zinc fingers 
and deacetylates K314. SIRT1 recruits also HDAC4 which facilitate SUMOylation of K314 (Fig. 1). Microglial cells 
were co-transfected with the indicated constructs and either episomal pLTR-Luc (A) or pNL-4.3 viral genome 
(B). 48-hours post-transfection, cells were lysed and subjected to luciferase assay, while normalized with renilla 
luciferase system (A) or supernatants were harvested and p24 concentration titrated (B). Values are normalized 
relatively to basal level corresponding to empty vector (A,B), lane1. HEK293T cells were transfected with pFlag-
HIC1 wild-type (C), lane 3 or the pFlag-HIC1 mutant K314Q (C), lane 4 in presence of TAT. Nuclear cell extracts 
were obtained after 48-hours transfection of the indicated vectors and subjected to western-blot experiments 
with anti-flag and anti-TAT antibodies (C), Inputs lanes 3 and 4. Cells were lysed and nuclear extracts have been 
subjected to immunoprecipitation with an anti-TAT antibody (C). Co-immunoprecipitations of Flagged HIC1 
wild type and K314Q mutant with TAT were compared by western-blot with respectively anti-flag and anti-TAT 
antibodies (C) IP Tat lanes 1 and 2).
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These observations support a cooperative function of HIC1 and HMGA1 in the regulation of cellular target 
genes in microglial cells. We performed co-immunoprecipitation experiments in order to determine whether 
HIC1 and HMGA1 interact in cells. As shown in Fig. 9D, HMGA1 was co- immunoprecipitated with HIC1 
suggesting a physical interaction between the two proteins. We next focused on other putative functional inter-
actions in the regulation of HIV-1 expression. We observed that a concomitant reduction of endogenous HIC1 
and HMGA1 promoted a strong synergistic stimulation of HIV-1 transcription (Fig. 9E, row 5 (74 folds) vs 2 
(Tat alone: 23 folds)). Of note, this effect was observed only if moderate amount of sh constructs (sh-HMGA1 
and Sh-HIC1) were used. In the experiments only modest raise of Tat-mediated activation was observed when 
sh-HMGA1 (34 fold) or sh-HIC1 (28 fold) were co-expressed with Tat (Fig. 9E, row 3 and 4 vs 2). To reinforce 
these results, we performed concomitant overexpression of HIC1 and HMGA1 in HIV-1 infected cells (Fig. 9F). 
As previously shown, even moderate overexpression of HIC1 and HMGA1 repressed HIV-1 expression (Fig. 9F, 
row 2 and 3 vs 1). Moreover, concomitant HIC1 and HMGA1 overexpression promoted a cooperative repression 
that inhibited more than 60% of HIV-1 expression. Taken together, our results suggest that HIC1 and HMGA1 
interact physically and functionally to repress HIV-1 and cellular gene expression.
Discussion
We show in this paper that the tumor suppressor protein HIC1 interacts physically with CTIP2 and HMGA1 to 
regulate subsets of cellular genes. Among the cellular target genes regulated by HIC1, CTIP2 and HMGA1 are 
several, which have been reported to be involved in HIV-1 infection. The tudor domain containing 7 (TDRD7) 
gene, which is down-regulated by HIC1 and CTIP2, belongs to a group of interferon-stimulated genes, which 
repress HIV-1 replication37. The interferon-induced transcription of the dickkopf homolog 1 (DKK1) gene, an 
antagonist of the beta-catenin pathway which is inhibited by HIC1 and CTIP2, activates HIV-1 LTR activity38. 
Repression of the cyclin-dependent kinase inhibitor 1A, which is regulated upon HIC1- CTIP2- and HMGA1 
overexpression, has been shown to impact the viral mRNA production in CD4+ T cells39. The regulation of these 
cellular target genes may support the Tat/TAR-dependent effect of HIC1, CTIP2 and HMGA1 on HIV-1 tran-
scriptional repression. Notably, 95 out of 100 genes within the common subset of HIC1 and CTIP2 targets are 
repressed by the overexpression of either protein and induced by the knockdown of the corresponding protein. 
Also in the case of the common subset of HIC1 and HMGA1 targets, the majority (17 out of 20) are repressed 
upon HIC1 and HMGA1 overexpression and activated by their knockdown, respectively. Both observations sup-
port a primarily repressive cooperativity of HIC1 and CTIP2 as well as of HIC1 and HMGA1 on cellular gene 
expression. However, this repressive effect on cellular genes most likely involves a different mechanism as com-
pared to the Tat/TAR-dependent HIV-1 repression, which needs to be further investigated in future studies.
Figure 8. The TAR RNA is a critical element of HIC1 inhibitory activity. Microglial cells were co-transfected 
with pLTR-luc in presence of TAT (lanes 2 to 6) with (lanes 3 and 6) or without HIC1 (lanes 1, 2, 4 and 5). The 
implication of the TAR element in the HIC1-mediated HIV-1 transcription was assessed by comparing HIC1 
repressive activity in absence (lanes 1, 2 and 3) or presence of free TAR RNA (lanes 4, 5 and 6). 48-hours post-
transfection, cells were lysed and luciferase activity measured. Values were normalized using renilla luciferase 
system.
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We also show that HIC1 is new transcriptional inhibitor acting during the late phase of Tat-dependent 
HIV1 transcription. We notably demonstrated that HIC1 repressive activity requires SIRT1 deacetylase activity 
in microglial cells. Moreover, a single mutation in the MK314HEP acetylation rendering HIC1 constitutively 
acetylated is sufficient to abolish HIC1 inhibitory effect. Constitutively acetylated HIC1, unlike HIC1 wild type, is 
neither able to repress Tat-mediated HIV-1 transcription nor to interact with Tat, although the SIRT1/HIC1 inter-
action still remains. It seems that SIRT1/HIC1 interaction may promote deacetylation of HIC1, which facilitates 
HIC1/Tat interaction. We also found that HIC1 is member of at least one TAR-containing complex (data not 
shown). Our results suggest that the TAR element may serve as HIC1 reservoir at the viral promoter to facili-
tate HIC1/TAT interaction. They also suggest that HIC1 repression of Tat function occurs in a TAR dependent 
manner.
Finally, we show that HIC1 interacts physically and functionally with HMGA1 to repress Tat dependent HIV-1 
transcription repression. Surprisingly, we could not observe a clear functional cooperation between CTIP2 and 
HIC1 on the control of HIV-1 replication (data not shown). Indeed we have previously shown that CTIP2 and 
HMGA1 acted synergistically to prevent HIV-1 reactivation5 and in the present paper that HMGA1 and HIC-1 
inhibited Tat-dependent transcription. These results suggest us that different complexes containing CTIP2, HIC1 
or HMGA1 alone or together either CTIP2 and HIC1, CTIP2 and HMGA1, and HIC1 and HMGA1 may exist to 
Figure 9. Cooperativity of HIC1 and HMGA1. (A) Venn-diagram of HIC1 and HMGA1 target genes. HIC1 
target genes (red) have been identified as indicated in Fig. 1A and HMGA1 target genes (green) have been 
defined as genes statistically significantly (p < 0.05) concordantly regulated genes upon overexpression and 
knockdown of HMGA1. The common subset is shown in yellow. The p-value (hypergeometric distribution) for 
chance occurrence of this overlap is indicated. (B) Scatter plot of the genes shown in A. The log2-fold change 
upon HIC1 overexpression is plotted against the x-axis, the log2-fold change upon HMGA1 overexpression is 
plotted against the y-axis. The Pearson correlation coefficient for each gene set is indicated (R). (C) As in (B) but 
comparing the log2-fold changes in gene expression upon HIC1 knockdown with the knockdown of HMGA1. 
(D) HMGA1 and HIC1 interact physically: HEK293T cells were transfected with the GFP-HMGA1 expression 
vector and the Flag-HIC1 expression vector (lane 2) or the control pCDNA3-Flag vector (lane 1). Complexes 
immunoprecipitated with the anti-Flag antibodies were immunodetected for the presence of Flag- HIC1 and 
HMGA1 proteins by Western blot as indicated. (E,F) HIC1 cooperates with HMGA1 to repress HIV-1 gene 
transcription and viral replication: Microglial cells were transfected either with the episomal pLTR-luciferase 
reporter (E) or the pNL-4.3 provirus (F) and the indicated plasmids. 48-hours later, cells were lysed (E) or 
supernatants were harvested (F). Relative HIV expression was measured through the titration of the viral p24 
concentrations in supernatant and normalized relatively to their appropriate empty vector control (F). Cell 
lysates were subjected to luciferase assay, normalized with the renilla luciferase system and expressed as relative 
value with their respective control (E).
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fulfill different functions. These different complexes reflect a dynamic process involved in fine-tuned regulation 
of both cellular and viral gene and might be related to posttranslational modification of these proteins. In favor 
to this hypothesis we showed that Protein Kinase C-Mediated phosphorylation of CTIP2 at Serine 2 negatively 
regulates its interaction with NuRD Complexes during CD4+ T-Cell activation40.
The precise mechanisms of the repression exerted by HIC1 alone or in association with HMGA1 is far to be 
elucidated and will need more investigations but we know that it is occurring in presence of Tat and is independ-
ent of P-TEFb (data not shown). HMGA1 alone is not able (Fig. 9E) or represses very faintly36 the late phase of the 
Tat dependent HIV1 transcription but requires the interaction with HIC1, which suggests a new role for HMGA1 
during HIV-1 transcription. A recent study indicated that HMGA1 interacts with TAR RNA Binding Protein 
(TRBP)41. In our opinion HMGA1 could be the link between HIC1 and HIV-1 TAR RNA through interaction 
with TRBP and will need further investigation.
The transcription inhibition mechanism has not been elucidated yet and may involve a complex interplay 
between HIC1, SIRT1, HMGA1 and Tat. SIRT1 and Tat are indeed known to interact at the end of the trans-
activation cycle. SIRT1 removes acetylation marks of lysine 28 and 50 of Tat allowing the recycling of the viral 
transactivator42. Deciphering the sequential process occurring between HIC1, SIRT1 and Tat would allow us to 
understand the modalities of HIC1-mediated Tat-transactivation repression in the prevention of HIV-1 silencing.
Finally, our results have allowed the identification of new potential targets for HIV-1 reactivation i.e. SIRT1 as 
well as HIC1 in a “shock and kill” strategy. Such a strategy aims to at least reduce the size of the cellular reservoir 
which might lead to a functional cure through the association of reactivation of HIV transcription (shock) to an 
intensifying cART and/or novel immunological approaches for HIV-1 eradication (kill)43,44. We and others have 
reported the efficiency of combined treatments for reactivating quiescent/latent HIV both in vitro, ex vivo and 
in vivo45–49 (reviewed in ref. 50).
Materials and Methods
Plasmids. Most of the constructs used in our assays have been previously described: pcDNA3, pFlag-TAT51, 
pGFP-TAT8, pFlag- CTIP26, pFlag-HIC1, pFlag-HIC1 K314Q, pFlag-HIC1 K314R, pFlag-HIC1 E316A28, the 
shHMGA1 and GFP-HMGA152,53, the pFlag-SIRT1 et pFlag-SIRT1 H363Y54, the episomal pLTR-Luc6, pNL-4.355. 
pshHIC1 and pshscramble control were manufactured by Suresilencing® (Qiagen). For luciferase assays we used 
as an internal control the reporter encoding the Renilla luciferase gene (Promega).
Cell culture. Human microglial cells56 and HEK293T cells were cultivated in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplied with 10% fetal calf serum and 100 U/ml penicillin-streptomycin.
Luciferase Assay. Microglial cells were cultivated in 48-wells plate and transfected with fixed amount of 
plasmid DNA using calcium phosphate precipitation technique. Nicotinamide (NA) treatment was performed 
24-hours after transfection. Cells were incubated with 10 mM NA or were mock treated with the proper diluent. 
48 hours post-transfection cells were subjected to Dual-Glo® Luciferase Assay System (Promega) and luciferase 
activity was measured. Values are representative of at least three independent experiments in at least duplicates. 
Basal activity which corresponds to transfection with only control vectors, were adjusted to one.
P24 ELISA assay. Microglial cells were cultivated in 48-wells plate and transfected with 1 μ g/well of plas-
mid DNA using calcium phosphate precipitation technique. 48 hours post-transfection cell supernatants were 
harvested and subjected to Innotest® p24 ELISA Assay (Innogenetics). Values are representative of at least three 
independent experiments in at least duplicates. Basal activity which corresponds to transfection with only control 
vectors, were set at one.
Co-immunoprecipitation assays. HEK293T cells were cultivated in 144 mm petri-dishes and transfected 
with 75 μ g of plasmid DNA using calcium phosphate precipitation method. 48-hours post-transfection cells were 
harvested and lysed to recover nuclear proteins. Nuclear extracts (1 mg) were incubated overnight at 4 °C with M2 
anti-Flag antibody (SIGMA), anti-TAT antibody (abcam) or anti-SIRT1 antibody (Millipore). Complex proteins/
antibody were washed with both high-salt (500 mM NaCl) and low salt (125 mM NaCl) buffers. Complexes were 
studied by SDS-PAGE and Western blot.
SDS-PAGE and Western blot analysis. SDS-PAGE was performed using standard procedures. 
Proteins were western-blotted with M2 anti-flag antibody (Sigma), anti-TAT antibody (abcam), anti-SIRT1 
antibody (Millipore) and anti-HMGA1 (abcam). Proteins were detected using the Super Signal West Dura® 
Chemiluminesence Detection System (Pierce biotech).
Immunocytochemistry and confocal microscopy. Microglial cells were cultivated on glass coverslips 
in 24-wells plate and transfected with Jetprime® (polyplus transfection) according to manufacturer protocol. 
48-hours post-transfection cell were fixed with PFA 4% and permeabilized with PFA4%/triton1%. Cells were 
incubated in BSA blocking buffer, then incubated 1 hour with primary mouse M2 anti-Flag antibody (Sigma) fol-
lowed by a 1-hour incubation with cyanine 3-labelled anti-mouse antibody. Finally, cells were incubated 30 min-
utes with TOPRO-3 to stained cell nucleus. Cells were washed with PBS between each step. Fluorescence was 
recorded by confocal microscopy using a Zeiss laser scanning microscope (model 510 invert) equipped with a 
Planapo oil (63x) immersion lens (numerical aperture = 1.4).
Gene expression profiling and data analysis. Total RNA from transfected microglial cells was pre-
pared using the RNeasy Midi Kit (Qiagen) as recommended by the manufacturer. The RNA was labelled using 
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the Illumina® TotalPrep™ RNA Amplification Kit (Ambion) according to the manufacturer instructions. For 
microarray analyses, hybridization and detection were performed following the protocols supplied by Illumina 
using the HumanHT-12 v4 Expression BeadChip Kit and an iScan system (both Illumina). The raw data were 
quality controlled57, NeoNORM normalized using k = 0.258, and analyzed as outlined in59. For subtraction profil-
ing we used the CDS statistical test60 with a positive False Discovery Rate correction where appropriate. Canonical 
pathway enrichment studies were performed using Ingenuity Pathway Analysis® software (Ingenuity® Systems) 
as recommended by the manufacturer. Transcriptome data were deposited in the public database MACE (http://
mace.ihes.fr) using Accession Nos.: 3037572262 (CTIP2 knock-down), 2166467750 (CTIP2 overexpression), 
3164892326 (HMGA1 knock-down), 2365090982 (HMGA1 overexpression), 2574019750 (HIC1 knock-down) 
and 3138153638 (HIC1 overexpression).
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